Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07197866
PHASE2

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

Sponsor: Teva Branded Pharmaceutical Products R&D LLC

View on ClinicalTrials.gov

Summary

The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286. The planned total duration of the trial is approximately 100 weeks.

Official title: An Open-Label Extension, Multi-Centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants With Multiple System Atrophy

Key Details

Gender

All

Age Range

30 Years - Any

Study Type

INTERVENTIONAL

Enrollment

200

Start Date

2025-09-30

Completion Date

2029-05-17

Last Updated

2026-04-09

Healthy Volunteers

No

Interventions

DRUG

TEV-56286

administered orally

Locations (11)

Teva Investigational Site 15544

Boca Raton, Florida, United States

Teva Investigational Site 15555

Tampa, Florida, United States

Teva Investigational Site 15543

Spokane, Washington, United States

Teva Investigational Site 35290

Bordeaux, France

Teva Investigational Site 32818

Dresden, Germany

Teva Investigational Site 80203

Haifa, Israel

Teva Investigational Site 30299

Bologna, Italy

Teva Investigational Site 84141

Sanda-shi, Japan

Teva Investigational Site 31324

Barcelona, Spain

Teva Investigational Site 31323

Barcelona, Spain

Teva Investigational Site 31322

Seville, Spain